oncgnostics GmbH
The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
oncgnostics GmbH is working according to ISO 13485 standards in research, development, production and management.
Recent Posts
Upcoming Events
-
EUROGIN 2023
8. February - 11. February
Contact
oncgnostics GmbH
Löbstedter Str. 41
07749 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]oncgnostics.com
Internet: www.oncgnostics.com
Test for cervical cancer ideal for clarification in case of positive HPV result
BlogIndependent study in cervical cancer screening: The GynTect test for cervical cancer screening is highly informative regarding whether cervical cancer is present or likely to develop. In addition, GynTect is well suited for sampling by the patient herself (self-sampling). All these points are confirmed by a recently published study from China. The Chinese diagnostics company […]
Cancer diagnostics of the future thanks to highly informative biomarkers
Press Releasesoncgnostics at Medica 2022: Cervical cancer screening test conquers China Establishing early detection of head and neck tumours First study results for screening test for vulva and vaginal cancer At the joint stand of medways e.V. in Hall 15, Stand K10 Jena / Düsseldorf, November 08, 2022 – oncgnostics GmbH will present its technology, products […]
World Sexual Health Day: Cancer is also an issue
BlogThere are many more aspects to the topic of sexual health than are apparent at first glance. We want to use World Sexual Health Day as an opportunity to draw attention to cervical cancer, which develops from a sexually transmitted HPV infection. Definition of sexual health The World Health Organization (WHO) defines sexual health as […]
German oncgnostics GmbH‘s innovation in the area of cervical cancer diagnostics now also available in China
Press ReleasesGynTect receives approval in China Jena, August 25, 2022 – The cervical cancer screening test GynTect is now available to physicians and patients in China, the world’s most populous country. The product is the first approved methylation test for triage of HPV-positive cases in China. GynTect was developed by oncgnostics GmbH and is already approved […]
Early detection of vulvar and vaginal cancer is overdue
BlogThere is still no targeted method for early detection of vulvar and vaginal cancer. This is despite the fact that an estimated 45,240 women worldwide were diagnosed with vulvar cancer in 2020, and more than 17,000 people even died from it. Vaginal cancer occurs slightly less frequently – with around 18,000 new cases and 8,000 […]
The IVDR (In-vitro Diagnostic Medical Device Regulation)
BlogThe new IVDR (In-vitro Diagnostic Medical Device Regulation) has been in force since 26 May. As a result, numerous companies have had to adapt their approval processes and internal procedures. The new regulations also present oncgnostics with new challenges. For example, the molecular biological cancer tests now fall into the second highest risk level. This […]
PCR test detects cervical precancerous lesions
Blog, Press ReleasesJena, Germany, May 25th 2022 – May 28 marks the 35th International Day of Action for Women’s Health. One “female” disease that should no longer exist due to the availability of modern cancer-screening methods is cervical cancer. One step in the direction of abolishing this form of cancer has been taken by the German life […]
WHO recommends one-dose HPV vaccination for girls
BlogThe World Health Organisation (WHO) recommends the one-dose HPV vaccination of girls and women up to 21 years of age instead of the current two-time vaccination. The WHO wants to increase the vaccination rate in the fight against cervical cancer. In principle, we welcome this plan, but we also have reservations regarding the new recommendation[1]. […]
oncgnostics at EUROGIN 2022
BlogThe EUROGIN is THE event for our current application areas and most of the experts were in Düsseldorf. So were we! With four presentations oncgnostics participated in the scientific discourse at the International multidisciplinary HPV Congress. The congress was again a great opportunity for us to make new contacts, maintain existing partnerships and exchange ideas […]
Oncgnostics receives award: Germany’s most innovative companies
BlogThe business magazine Capital selected Germany’s most innovative companies for the third time. Oncgnostics GmbH made it into the selection. The biotech company scored particularly well in the evaluation criterion of innovation areas. For the third time, Capital, together with the market research institute Statista, determined Germany’s most innovative companies. For this purpose, they brought […]